Bauer Jake 4

What Happened
Jake Bauer, a director of BridgeBio Oncology Therapeutics, Inc. (BBOT), was granted a derivative award (stock option) for 31,675 shares on 2026-06-16. The filing reports an acquisition price of $0.00 and a reported value of $0, which reflects a grant of an equity award rather than a market purchase or sale.

Key Details

• Transaction type: Award/Grant of a derivative security (code A).
• Date of transaction: 2026-06-16; Form 4 filed: 2026-06-18 (timely filing).
• Shares involved: 31,675 underlying shares reported. Price: $0.00 (grant recorded as derivative award).
• Shares owned after transaction: Not specified in the filing.
• Footnote: The shares underlying the stock option vest in full upon the earlier of (i) the first anniversary of the grant or (ii) the date of the next Annual Meeting of Stockholders, subject to continued service.
• Exhibit: Exhibit 24 — Power of Attorney included with the filing.

Context
This was a grant of a derivative award (stock option), not a cash purchase or sale; no shares were exercised or sold at the time of the filing. Such grants are commonly part of director compensation and vest on a schedule tied to continued service, so they do not by themselves indicate an immediate change in insider market exposure or sentiment.